Vanda Pharmaceuticals (NASDAQ:VNDA) will report earnings before markets open on Thursday, May 9th. Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.
Here is your Cheat Sheet to Vanda Pharmaceuticals Earnings:
Earnings Expectations: Analysts expect earnings of $-0.25 per share on revenues of $8.41 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.11 to a loss $0.25. For the current year, the average estimate is a loss of $0.89, which is worse than the estimate ninety days ago.
Here’s how Vanda Pharmaceuticals has been performing on an annual basis:
|Revenue ($) in millions||0.00||4.55||35.71||31.27||32.73|
|Diluted EPS ($)||-1.92||-1.33||0.25||-0.35||-0.98|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||8.37||8.14||8.38||8.29||7.92|
|Diluted EPS ($)||-0.1965||-0.28||-0.28||-0.19||-0.2256|
Vanda Pharmaceuticals has missed analyst estimates 3 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)